文献速递细菌感染、耐药与抗菌药物医院感染防控

西格列汀减弱脲酶相关表型并增强美罗培南对多重耐药革兰阴性临床分离株的活性:一项初步药物再利用研究

Sitagliptin attenuates urease-associated phenotypes and potentiates meropenem in multidrug-resistant Gram-negative clinical isolates: a preliminary repurposing study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该初步研究在测试的制备物和分离株面板中,评估了DPP-4抑制剂西格列汀对奇异变形杆菌脲酶相关表型及美罗培南抗多重耐药革兰阴性临床分离株活性的影响。西格列汀在2000 µg/mL(其MIC的1/8)下抑制脲酶相关信号53.2%-55.2%,降低人工尿液中脲酶驱动的pH升高,减少导管相关生物量83.6%,并使美罗培南MIC降低16-至64倍(FICI 0.1406-0.1875)。

要点

  • 西格列汀在2000 µg/mL下抑制脲酶相关信号53.2%-55.2%,并减少导管相关生物量83.6%。
  • 西格列汀使美罗培南MIC降低16-至64倍,FICI为0.1406-0.1875,显示协同作用。
  • 西格列汀降低ureR、ureC、blaNDM、blaIMP和blaVIM的相对转录本丰度。

核心结论

  • 在测试的制备物和分离株面板中,西格列汀减弱脲酶相关表型,降低表观美罗培南水解活性并增强美罗培南活性。
  • 结果支持将西格列汀作为潜在抗毒力及抗生素辅助候选药物进一步研究。

研究设计与样本

  • 初步药物再利用研究,评估西格列汀对奇异变形杆菌脲酶相关表型及美罗培南对多重耐药革兰阴性临床分离株的增强作用。
  • 采用全细胞悬液和粗裂解物评估脲酶相关活性,并检测人工尿液中碱化、晶体形成及导管相关总生物量。
  • 通过联合纸片法和棋盘法评估美罗培南增强作用,并测定美罗培南水解活性。
  • 采用定量逆转录PCR评估相对转录本丰度,并使用分子对接生成结构假设。
  • 采用MTT法评估Vero细胞代谢活性。

主要发现

  • 西格列汀(2000 µg/mL;其MIC的1/8)在全细胞悬液和粗裂解物中抑制脲酶相关检测信号53.2%-55.2%。
  • 西格列汀使24小时后脲酶驱动的pH升高从9.21降至7.34,并使结晶紫染色的导管相关生物量减少83.6%。
  • 西格列汀使周质提取物中表观美罗培南水解信号降低33%-55%,并在联合试验中使美罗培南MIC降低16-至64倍,FICI值为0.1406-0.1875。
  • 在Vero细胞试验中,2000 µg/mL下细胞活力为94.4%,在测试范围内未观察到活力降低50%。
  • 西格列汀暴露与ureR、ureC、blaNDM、blaIMP和blaVIM的相对转录本丰度降低相关;对接生成靠近催化金属中心的结合构象。

关键数值与推荐

  • 西格列汀浓度2000 µg/mL相当于其MIC的1/8。
  • 脲酶相关检测信号抑制率为53.2%-55.2%。
  • 24小时后脲酶驱动的pH升高从9.21降至7.34。
  • 导管相关生物量减少83.6%。
  • 美罗培南MIC降低16-至64倍,FICI值为0.1406-0.1875;Vero细胞活力在2000 µg/mL下为94.4%。

临床怎么用

  • 在测试的制备物和分离株面板中,西格列汀表现出抗毒力和抗生素辅助潜力,但尚未支持临床常规使用。
  • 需进一步研究以确认西格列汀在临床相关感染模型中的疗效和安全性。

局限性

  • 该研究为初步药物再利用研究,结果需在更广泛的面板和体内模型中验证。
  • 研究仅测试了特定制备物和分离株面板,外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Urease contributes to urinary tract pathogenesis and catheter encrustation, whereas metallo-β-lactamases contribute to carbapenem resistance. OBJECTIVES: We investigated whether the dipeptidyl peptidase-4 inhibitor sitagliptin attenuates urease-associated phenotypes and potentiates meropenem against selected multidrug-resistant Gram-negative clinical isolates. METHODS: Urease-associated activity was assessed in whole-cell suspensions and crude lysates of Proteus mirabilis. Alkalinization, crystal formation in artificial urine, and catheter-associated total biomass were also examined. Meropenem potentiation was evaluated by combined-disk and chequerboard assays, and meropenem-hydrolyzing activity was measured. Relative transcript abundance was assessed by quantitative reverse-transcription PCR, and docking was used to generate structural hypotheses. Vero-cell metabolic activity was evaluated by the MTT assay. RESULTS: Sitagliptin (2000 µg/mL; one-eighth of its MIC) inhibited urease-associated assay signal by 53.2%-55.2% in whole-cell suspensions and crude lysates, reduced the urease-driven pH increase from 9.21 to 7.34 after 24 h, and reduced crystal-violet-stained catheter-associated biomass by 83.6%. It reduced the apparent meropenem hydrolysis signal in periplasmic extracts by 33%-55% and reduced meropenem MICs by 16- to 64-fold in combination assays, with FICI values of 0.1406-0.1875. In the Vero-cell assay, viability at 2000 µg/mL was 94.4%, and a 50% reduction in viability was not observed within the tested range. Sitagliptin exposure was associated with reduced relative transcript abundance of ureR, ureC, blaNDM, blaIMP, and blaVIM. Docking generated binding poses near catalytic metal centres. CONCLUSIONS: In the tested preparations and isolate panel, sitagliptin attenuated urease-associated phenotypes, reduced apparent meropenem-hydrolyzing activity and potentiated meropenem, supporting its further investigation as a potential anti-virulence and antibiotic-adjuvant candidate.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Eladl A, Abbas HA, Abd El-Hamid MI, et al. Sitagliptin attenuates urease-associated phenotypes and potentiates meropenem in multidrug-resistant Gram-negative clinical isolates: a preliminary repurposing study. J Antimicrob Chemother. 2026. PMID: 42885748. doi:10.1093/jac/dkag344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。